Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caron A Jacobson

Showing results (111-120 of 140) with videos related to

Pageof 14
Sort By:
Blood Advances|October 31, 2025
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell LymphomaJ Erika Haydu, Robert A Redd, Matthew M Lei, et al.
Blood|April 7, 2019
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantationPhilippe Armand, Yi-Bin Chen, Robert A Redd, et al.
Nature Biotechnology|July 30, 2024
A CAR enhancer increases the activity and persistence of CAR T cellsTaha Rakhshandehroo, Shreya R Mantri, Heydar Moravej, et al.
Annals of Hematology|October 18, 2023
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphomaReid W Merryman, Robert A Redd, Arnold S Freedman, et al.
Journal for Immunotherapy of Cancer|February 18, 2026
Antigen-IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2RαHeydar Moravej, Taha Rakhshandehroo, Radia M M Khan, et al.
Transplantation and Cellular Therapy|October 20, 2021
Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with LymphomaReid W Merryman, Robert Redd, Erin Jeter, et al.
Blood Advances|February 10, 2025
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphomaMatthew J Frigault, Ning Yao, Trisha R Berger, et al.
Hemasphere|January 30, 2023
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular LymphomaReid W Merryman, Laure Michaud, Robert Redd, et al.
Blood Advances|April 3, 2025
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemiaJames T Yoon, Yinglu Zhou, Mariia Mikhaleva, et al.
Blood Advances|November 18, 2022
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantationReid W Merryman, Robert A Redd, Eleanor Taranto, et al.
Pageof 14

Showing results (111-120 of 140) with videos related to

Sort By:
Pageof 14
Blood Advances|October 31, 2025
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell LymphomaJ Erika Haydu, Robert A Redd, Matthew M Lei, et al.
Blood|April 7, 2019
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantationPhilippe Armand, Yi-Bin Chen, Robert A Redd, et al.
Nature Biotechnology|July 30, 2024
A CAR enhancer increases the activity and persistence of CAR T cellsTaha Rakhshandehroo, Shreya R Mantri, Heydar Moravej, et al.
Annals of Hematology|October 18, 2023
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphomaReid W Merryman, Robert A Redd, Arnold S Freedman, et al.
Journal for Immunotherapy of Cancer|February 18, 2026
Antigen-IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2RαHeydar Moravej, Taha Rakhshandehroo, Radia M M Khan, et al.
Transplantation and Cellular Therapy|October 20, 2021
Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with LymphomaReid W Merryman, Robert Redd, Erin Jeter, et al.
Blood Advances|February 10, 2025
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphomaMatthew J Frigault, Ning Yao, Trisha R Berger, et al.
Hemasphere|January 30, 2023
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular LymphomaReid W Merryman, Laure Michaud, Robert Redd, et al.
Blood Advances|April 3, 2025
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemiaJames T Yoon, Yinglu Zhou, Mariia Mikhaleva, et al.
Blood Advances|November 18, 2022
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantationReid W Merryman, Robert A Redd, Eleanor Taranto, et al.
Pageof 14